BioLineRx reports Q2 EPS 0c vs. 0c last year

Reports Q2 revenue $300K, consensus $661.33K. As of June 30, 2025, the company had cash, cash equivalents, and short-term bank deposits of $28.2M, sufficient to fund operations, as currently planned, into the first half of 2027. “Since our last quarterly update, we have been acutely focused on evaluating a broad range of potential pipeline expansion opportunities where we can leverage our clinical and regulatory expertise, and track record of drug approval success, to drive new innovation in areas of need,” said Philip Serlin, CEO. “Today, I am pleased to report that discussions with potential partners continue to progress. Our balance sheet is strong, our organization is lean, and we are seeing promising opportunities that fit well within our criteria – most notably a clear and efficient development pathway. I remain confident that we could potentially execute a transaction this year that will expand our pipeline and provide fresh opportunities for clinical success and long-term value creation.”